03.01.07
Next Pharmaceuticals has released the results of a clinical trial on its new patented heart health ingredient Flavoxine. The principal investigator for the trial was Dr. Julius Oben, head of the department of biochemistry, University of Yaounde in Cameroon. The double-blind placebo-controlled clinical trial with 80 subjects showed that Flavoxine significantly increased HDL-cholesterol, the so-called “good” cholesterol, while significantly reducing LDL-cholesterol, the so-called “bad” cholesterol, and triglycerides. In addition, Flavoxine significantly reduced C-reactive protein (CRP), an indicator of inflammation that is now considered to be another positive risk factor for coronary artery disease, and it significantly lowered blood pressure and fasting blood glucose in the overweight individuals with elevated cholesterol levels.
Flavoxine is a blend of two plant extracts, a proprietary extract of Phellodendron amurense and a patented (U.S. Patent No. 6,987,125) extract of orange peel containing polymethoxylated flavones.
Next Pharmaceuticals is seeking to replicate the trial in the U.S., through a joint effort with an academic institution under a National Institutes of Health (NIH) grant.
For further information: 415-454-2243.
Flavoxine is a blend of two plant extracts, a proprietary extract of Phellodendron amurense and a patented (U.S. Patent No. 6,987,125) extract of orange peel containing polymethoxylated flavones.
Next Pharmaceuticals is seeking to replicate the trial in the U.S., through a joint effort with an academic institution under a National Institutes of Health (NIH) grant.
For further information: 415-454-2243.